These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8470295)

  • 1. Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3.
    Agarwal RK; Ostaszewski ML; Feld LG; Springate JE; Moxey-Mims MM; O'Neil KM
    Transplant Proc; 1993 Apr; 25(2):2143-4. PubMed ID: 8470295
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased levels of sTNF receptors following OKT3 treatment.
    Bemelman FJ; Jansen J; van der Poll T; Hack CE; van Deventer SJ; ten Berge RJ
    Transplant Proc; 1994 Dec; 26(6):3094-5. PubMed ID: 7998082
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
    Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
    Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
    Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
    [No Abstract]   [Full Text] [Related]  

  • 5. Encephalopathy and cerebral infarction in OKT3-treated patients with concomitant elevation of cerebrospinal fluid tumour necrosis factor alpha.
    Reiss R; Makoff D; Rodriguez H; Graham S; Mittleman J; Jordan S
    Nephrol Dial Transplant; 1993; 8(5):464-8. PubMed ID: 8393555
    [No Abstract]   [Full Text] [Related]  

  • 6. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients.
    Kumano K; Irie A; Mashimo S; Endo T; Koshiba K
    Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of maintenance immunosuppression and methylprednisolone in OKT3-induced cytokine release.
    Peces R; Urra JM; Gorostidi M; López-Larrea C
    Transplant Proc; 1992 Dec; 24(6):2596-9. PubMed ID: 1465877
    [No Abstract]   [Full Text] [Related]  

  • 9. Encephalopathy following the use of OKT3 in renal allograft transplantation.
    Shihab FS; Barry JM; Norman DJ
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):31-4. PubMed ID: 8465419
    [No Abstract]   [Full Text] [Related]  

  • 10. Reduction of the initial febrile response to OKT3 with indomethacin.
    First MR; Schroeder TJ; Hariharan S; Weiskittel P
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):52-4. PubMed ID: 8465426
    [No Abstract]   [Full Text] [Related]  

  • 11. Proliferation rate of cells in the interstitial infiltrate in acute kidney allograft rejection.
    Olsen S; Hansen HE
    Transplant Proc; 1996 Feb; 28(1):502-3. PubMed ID: 8644329
    [No Abstract]   [Full Text] [Related]  

  • 12. Pentoxifylline reduces the first-dose reactions following OKT3.
    Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of steroid resistant acute rejection after renal transplantation.
    Oh CK; Kim YS; Kim MS; Kim SI; Park K
    Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737
    [No Abstract]   [Full Text] [Related]  

  • 14. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients.
    Leimenstoll G; Zabel P; Schroeder P; Schlaak M; Niedermayer W
    Transplant Proc; 1993 Feb; 25(1 Pt 1):561-3. PubMed ID: 8438414
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
    Kitabayashi K; Munn SR; Sterioff S
    Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.
    Jeffrey RF; Johnson MH; Bamford JM; Giles GR; Brownjohn AM; Will EJ
    Transplantation; 1993 Mar; 55(3):677-9. PubMed ID: 8456493
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of coagulation and fibrinolysis during treatment with OKT3.
    ten Berge RJ; Raasveld MH; van Diepen FN; Hack CE
    Transplant Proc; 1993 Feb; 25(1 Pt 1):566-7. PubMed ID: 8438416
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
    Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A
    Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.